Japan's Mitsubishi Tanabe Plans Scaled Entry Into U.S. Market
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma has plans to enter the U.S. pharmaceutical market in two years, beginning with a pair of drugs to treat kidney problems. To market the drugs, Mitsubishi Tanabe also plans to set up a U.S.-based sales unit and hire 100 representatives. The company expects to apply next year for U.S. approval of a hyperphosphatemia drug to treat kidney dysfunction as its first product. A year later, it plans to file for a treatment for chronic kidney failure with the hope of launching both drugs in 2012 or 2013. Longer-range plans call for introducing a diabetes treatment, along with entering into marketing agreements and acquiring U.S. companies. (Click here for more - a subscription may be required
You may also be interested in...
US FDA could revoke orphan designation or exclusivity if cost recovery requirements were not satisfied under bill unanimously passed by the House Energy and Commerce Committee.
Officials explain how remote record reviews, site transfers and other factors can green-light approvals of drugs and biologics.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.